Skip to main content
spacbrain

Jasper Therapeutics

Closed (deSPAC)

Health Care · clinical-stage biopharmaceutical company

What it is
Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases
What it’s doing now
Merging with Amplitude Healthcare Acquisition Corp (AMHC) — closed (despac).
What you should know
The deal carries a $130M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently evaluating briquilimab as a treatment in patients with CSU, CIndU and asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU, CIndU and allergic asthma. For more information, please visit us at www.jaspertx.com. 2

Source: S-4/A, accession 0001213900-21-044732

What the company says about itself

Web research — not audited

Jasper Therapeutics is a biotechnology company focused on targeting mast cells to treat chronic mast cell-driven diseases. Its lead candidate, briquilimab, is a targeted anti-KIT monoclonal antibody designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. The company is currently conducting clinical studies in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma.

Markets:
biotechnology | biopharma
Products:
briquilimab
What our web check found

[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Jasper completed a concurrent PIPE financing raising $132 million in gross proceeds." [https://www.stocktitan.net/sec-filings/JSPR/8-k-jasper-therapeutics-inc-reports-material-event-efbf61deb993.html]

Source: https://jaspertx.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Jasper Therapeutics is merging with Amplitude Healthcare Acquisition Corp (AMHC) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $100M · unsourced
Minimum cash to close$130M

Structure per SEC accession(s) 0001213900-21-031319. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Jasper Therapeutics going public?

Jasper Therapeutics has an approved merger with the SPAC Amplitude Healthcare Acquisition Corp (AMHC). Deal status: Closed (deSPAC).

Does Jasper Therapeutics have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals